FDA Approves Eli Lilly’s Alzheimer’s Drug
- July 12, 2024
The Food and Drug Administration (FDA) approved July 2 Eli Lilly & Company’s drug donanemab, a monoclonal antibody with the brand name Kisunla™, for treating Alzheimer’s disease.
ARTICLE TAGS
You must be logged in to access this content.